Differences in gene expression profiles from asbestos-treated SPARC-null and wild-type mouse lungs

Mark A. Pershouse; Aubrey M. Smartt; Corbin Schwanke; Elizabeth A. Putnam

doi:10.1016/j.ygeno.2009.04.009

Differences in gene expression profiles from asbestos-treated SPARC-null and wild-type mouse lungs

Mark A. Pershouse
, Aubrey M. Smartt
, Corbin Schwanke
, Elizabeth A. Putnam

Biomedical and Pharmaceutical Sciences

University of Montana

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The role of SPARC in the in vivo lung response to crocidolite asbestos was addressed by instillation of crocidolite asbestos in a series of wild-type or SPARC-null mice. Animals were sacrificed at one week, one month, and three months post-instillation to assess the impact of SPARC on multiple stages in the development of fibrosis. RNA was harvested from 10 animals/time point, pooled, and used to probe a mouse array containing ∼ 10,000 probes. Gene expression data were analyzed for fold change, and for broader functional group alterations. As expected, the one-week time point displayed alterations in genes involved in immune recognition, energy utilization, and growth factor production. Later time points showed expression alterations for genes involved in protein degradation, Wnt receptor signaling, membrane protein activity, and transport. Molecules in the Wnt pathway have been implicated in bone growth, mediation of fibroblast activity, and have been directly linked to SPARC regulation.

Original language	English
Pages (from-to)	101-109
Number of pages	9
Journal	Genomics
Volume	94
Issue number	2
DOIs	https://doi.org/10.1016/j.ygeno.2009.04.009
State	Published - Aug 2009

Funding

The authors acknowledge E. Helene Sage (Bennaroya Research Institute at Virginia Mason) for the kind gift of the SPARC-null mice. Support towards the publication of this manuscript came from the Montana NSF EPSCoR grant: EPS-03464558 and the State of Montana MBRCT grant: Agreement #07-04 (2004-2007) (MP and EAP); and the CDC through a subproject under grant number CCR822092 (EP). This publication was also made possible by both subproject (MP and EAP) and core facility (MP) support from Grant Number P20RR017670 and core facility support (MP) from Grant Number P20RR015583, both from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). The views expressed in this publication do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Funders	Funder number
Centers for Disease Control and Prevention	CCR822092
R21ES011676
P20RR015583, P20RR017670
07-04 (2004-2007, EPS-03464558

Keywords

Amphibole
Asbestos
Fibrosis
Hevin
Knockout mice
Microarray analysis
Osteonectin
SPARC

Access to Document

10.1016/j.ygeno.2009.04.009

Cite this

@article{3741e53f5dcf435a864ad513639f0e92,

title = "Differences in gene expression profiles from asbestos-treated SPARC-null and wild-type mouse lungs",

abstract = "The role of SPARC in the in vivo lung response to crocidolite asbestos was addressed by instillation of crocidolite asbestos in a series of wild-type or SPARC-null mice. Animals were sacrificed at one week, one month, and three months post-instillation to assess the impact of SPARC on multiple stages in the development of fibrosis. RNA was harvested from 10 animals/time point, pooled, and used to probe a mouse array containing ∼ 10,000 probes. Gene expression data were analyzed for fold change, and for broader functional group alterations. As expected, the one-week time point displayed alterations in genes involved in immune recognition, energy utilization, and growth factor production. Later time points showed expression alterations for genes involved in protein degradation, Wnt receptor signaling, membrane protein activity, and transport. Molecules in the Wnt pathway have been implicated in bone growth, mediation of fibroblast activity, and have been directly linked to SPARC regulation.",

keywords = "Amphibole, Asbestos, Fibrosis, Hevin, Knockout mice, Microarray analysis, Osteonectin, SPARC",

author = "Pershouse, \{Mark A.\} and Smartt, \{Aubrey M.\} and Corbin Schwanke and Putnam, \{Elizabeth A.\}",

note = "Funding Information: The authors acknowledge E. Helene Sage (Bennaroya Research Institute at Virginia Mason) for the kind gift of the SPARC-null mice. Support towards the publication of this manuscript came from the Montana NSF EPSCoR grant: EPS-03464558 and the State of Montana MBRCT grant: Agreement \#07-04 (2004-2007) (MP and EAP); and the CDC through a subproject under grant number CCR822092 (EP). This publication was also made possible by both subproject (MP and EAP) and core facility (MP) support from Grant Number P20RR017670 and core facility support (MP) from Grant Number P20RR015583, both from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). The views expressed in this publication do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.",

year = "2009",

month = aug,

doi = "10.1016/j.ygeno.2009.04.009",

language = "English",

volume = "94",

pages = "101--109",

journal = "Genomics",

issn = "0888-7543",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Differences in gene expression profiles from asbestos-treated SPARC-null and wild-type mouse lungs

AU - Pershouse, Mark A.

AU - Smartt, Aubrey M.

AU - Schwanke, Corbin

AU - Putnam, Elizabeth A.

N1 - Funding Information: The authors acknowledge E. Helene Sage (Bennaroya Research Institute at Virginia Mason) for the kind gift of the SPARC-null mice. Support towards the publication of this manuscript came from the Montana NSF EPSCoR grant: EPS-03464558 and the State of Montana MBRCT grant: Agreement #07-04 (2004-2007) (MP and EAP); and the CDC through a subproject under grant number CCR822092 (EP). This publication was also made possible by both subproject (MP and EAP) and core facility (MP) support from Grant Number P20RR017670 and core facility support (MP) from Grant Number P20RR015583, both from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). The views expressed in this publication do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

PY - 2009/8

Y1 - 2009/8

N2 - The role of SPARC in the in vivo lung response to crocidolite asbestos was addressed by instillation of crocidolite asbestos in a series of wild-type or SPARC-null mice. Animals were sacrificed at one week, one month, and three months post-instillation to assess the impact of SPARC on multiple stages in the development of fibrosis. RNA was harvested from 10 animals/time point, pooled, and used to probe a mouse array containing ∼ 10,000 probes. Gene expression data were analyzed for fold change, and for broader functional group alterations. As expected, the one-week time point displayed alterations in genes involved in immune recognition, energy utilization, and growth factor production. Later time points showed expression alterations for genes involved in protein degradation, Wnt receptor signaling, membrane protein activity, and transport. Molecules in the Wnt pathway have been implicated in bone growth, mediation of fibroblast activity, and have been directly linked to SPARC regulation.

AB - The role of SPARC in the in vivo lung response to crocidolite asbestos was addressed by instillation of crocidolite asbestos in a series of wild-type or SPARC-null mice. Animals were sacrificed at one week, one month, and three months post-instillation to assess the impact of SPARC on multiple stages in the development of fibrosis. RNA was harvested from 10 animals/time point, pooled, and used to probe a mouse array containing ∼ 10,000 probes. Gene expression data were analyzed for fold change, and for broader functional group alterations. As expected, the one-week time point displayed alterations in genes involved in immune recognition, energy utilization, and growth factor production. Later time points showed expression alterations for genes involved in protein degradation, Wnt receptor signaling, membrane protein activity, and transport. Molecules in the Wnt pathway have been implicated in bone growth, mediation of fibroblast activity, and have been directly linked to SPARC regulation.

KW - Amphibole

KW - Asbestos

KW - Fibrosis

KW - Hevin

KW - Knockout mice

KW - Microarray analysis

KW - Osteonectin

KW - SPARC

UR - https://www.scopus.com/pages/publications/67649976601

U2 - 10.1016/j.ygeno.2009.04.009

DO - 10.1016/j.ygeno.2009.04.009

M3 - Article

C2 - 19446018

AN - SCOPUS:67649976601

SN - 0888-7543

VL - 94

SP - 101

EP - 109

JO - Genomics

JF - Genomics

IS - 2

ER -

Differences in gene expression profiles from asbestos-treated SPARC-null and wild-type mouse lungs

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this